Sun Pharma Evaluates $10 Billion Acquisition of US-Based Organon to Expand Presence

Sun Pharmaceutical Industries Ltd is considering acquiring US-based Organon, a women's healthcare specialist with a growing biosimilars portfolio, in a deal valued around USD 10 billion including debt. This potential acquisition, the largest cross-border deal in India's pharmaceutical sector, aims to strengthen Sun Pharma's US presence. Organon, spun off from MSD in 2021 with significant debt, has pursued inorganic growth and is divesting non-core assets. The deal is described as transformative, with financial proposals being prepared for Organon's board amid recent leadership changes.